The verdict
Our read at a glance.
Whether internet TB-500 recovery claims are supported by evidence from the same product identity, or whether they are borrowing from full-length thymosin beta-4, named investigational products, or fragment biology that should not be treated as interchangeable.
- The signal
- Human evidence is product- and indication-specific, mostly involving full-length thymosin beta-4 or named investigational products in ocular, wound, dermatologic, and selected cardiac contexts. Preclinical evidence is broad, but it does not prove broad TB-500 recovery claims.
- The unknown
- Whether any real-world TB-500 fragment product matches studied material, whether human outcome evidence exists for the claimed recovery uses, and how to interpret safety when identity, purity, aggregation, impurities, and product characterization are uncertain.
- Our read
- The Watchlist read is not that thymosin beta-4 biology is uninteresting. It is that internet TB-500 claims often collapse different molecules and products into one story. The evidence must stay product-specific.
The explainer
Watch the 15:13 explainer.
6.0K views · May 2026
The mechanism
How it works.
TB-500 is marketed as a short fragment (the sequence LKKTETQ) of thymosin beta-4, a natural peptide whose main job is to bind actin, a structural protein that lets cells move and reshape themselves. Full-length thymosin beta-4 has been studied for cell migration, wound repair, new blood-vessel formation, and dampening inflammation in injured-tissue models. The key catch is that the actin-binding evidence belongs to the full-length molecule, and a short fragment sold as TB-500 cannot be assumed to reproduce that biology in humans.
Safety & regulatory boundary
The consequential part.
FDA lists thymosin beta-4 fragment (LKKTETQ), also known as TB-500, among withdrawn nominated bulk substances that may present significant safety risks and notes missing human exposure data plus immunogenicity, aggregation, and peptide-impurity concerns. FDA PCAC is scheduled to discuss TB-500 free base/acetate on July 23, 2026; that is not a completed decision.
What's next
What we're watching.
Exact-product human trials, full publications for named investigational products, the July 23, 2026 FDA PCAC discussion, and better product-identity characterization.
Context
Why this is discussed.
Recovery and tissue-repair narratives are common online, especially around musculoskeletal use, because thymosin beta-4 biology has plausible repair mechanisms and narrow clinical-development programs.
The evidence base
63 cited references.
Regulatory & labels9
U.S. Food and Drug Administration · Current FDA page
U.S. Food and Drug Administration · Current FDA page
U.S. Food and Drug Administration · Updated 2026-05-14
U.S. Food and Drug Administration · 2026 scheduled meeting
U.S. Food and Drug Administration · Designated 2013-12-31
Therapeutic Goods Administration · 2026-04-13
Therapeutic Goods Administration · 2016
Medsafe, New Zealand · 2017-05-16
World Anti-Doping Agency · Effective 2026-01-01
Registered trials5
ClinicalTrials.gov / ReGenTree · NCT01387347
ClinicalTrials.gov / ReGenTree · NCT02974907
ClinicalTrials.gov / RegeneRx Biopharmaceuticals · NCT00832091
ClinicalTrials.gov / RegeneRx Biopharmaceuticals · NCT01311518
ClinicalTrials.gov / Beijing Northland Biotech · NCT05485818
Peer-reviewed journals2
Sosne, Kleinman, Springs, Gross, Sung, and Kang · 2023
Bock-Marquette et al. · 2004
Indexed literature (PubMed)42
Review authors · 2021
Review authors · 2023
Sosne and Ousler · 2015
Guarnera, De Rosa, Camerini, and collaborators · 2010
Dunn et al. · 2010
Yu et al. · 2021
Zhang et al. · 2025
Guarnera, De Rosa, and Camerini · 2007
Goldstein, Hannappel, and Kleinman · 2005
Kleinman and Sosne · 2016
Sosne, Rimmer, Kleinman, and Ousler · 2016
Xing, Ye, Zuo, and Li · 2021
Bjorklund, Dadar, Aaseth, and Chirumbolo · 2020
Kim and Jung · 2015
Prodinger, Bauer, and Laimer · 2020
Mendias and Awan · 2026
Tan et al. · 2018
Belsky et al. · 2018
Lenfant et al. · 1991
Expert Opinion review authors · 2015
Kassem et al. · 2019
Esposito, Deventer, Goeman, Van der Eycken, and Van Eenoo · 2012
Ho et al. · 2012
Davison and Brown · 2013
Malinda et al. · 1999
Malinda et al. · 1997
Philp et al. · 2003
Philp et al. · 2004
Sosne et al. · 2010
Freeman et al. · 2011
Sosne et al. · 2005
Sosne and Kleinman · 2015
Kim et al. · 2018
Wang et al. · 2022
Smart et al. · 2007
Wu et al. · 2020
Shah et al. · 2018
Vasilopoulou et al. · 2016
Yu et al. · 2025
Wang, Banga, Ebrahim, Carion, Sosne, and Berger · 2024
Sponsor & other sources5
PubChem / National Center for Biotechnology Information · Current database record
PubChem / National Center for Biotechnology Information · Current database record
PubChem / National Center for Biotechnology Information · Current database record
National Center for Biotechnology Information · Updated 2026-04-12
UniProtKB / Swiss-Prot · Annotation update 2026-01-28
Keep reading